Linked research, clinical, and regulatory source pathways.
Company profile
About Oviva
Oviva is Europe's leading digital health provider for weight-related conditions, making evidence-based care accessible to everyone who needs it—reimbursed, at scale, and proven. Founded in 2014 by Kai Eberhardt and Manuel Baumann, the company has significantly improved the lives of more than 1 million patients across Germany, the UK, and Switzerland, backed by 100+ peer-reviewed publications. Oviva's AI-enabled care combines a medical-device-certified app with clinical teams of doctors, dietitians, and behavioural specialists. The platform provides personalised dietary advice combined with unique digital tools to help patients change their habits and improve their health long-term. The company's approach is reimbursed as a certified DiGA (Digital Health Application) in Germany, delivered in partnership with the NHS in the UK, and integrated into Swiss public healthcare. The company treats obesity, hypertension, and type 2 diabetes, expanding further to become the long-term partner for chronic care in Europe. Oviva's services include digital Tier 3 Weight Management, NHS Diabetes Prevention Programme, diabetes remission services, and virtual clinics offering medical support therapy. With over 420 experienced dietitians, psychologists, and doctors, Oviva maintains a 97% recommendation rate from patients. The company operates across multiple European markets with offices in Zurich, Altendorf, London, Berlin, Potsdam, and Warsaw.
Company description Oviva official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- High cholesterol
- Hypertension
- Obesity
- PCOS
- Type 2 diabetes
- Weight-related conditions
Who it serves
- Government healthcare
- Health Systems
- Payers
- Providers
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: ePA 3.0 (electronic patient record), RISE Technology, Telematikinfrastruktur (Germany).
Geographic context
Company milestones
Platform expansion
Surpassed 1 million patients treated (July 2025). Secured €200 million Series D funding (January 2026). Hypertension DiGA approved by BfArM (January 2026). Reached 124,700 prescriptions in 2024, ranking #1 in DiGA market. Launched virtual Oviva Clinics in UK and Switzerland (2024). Expanded to weight loss medication support services.
Partnerships
Recorded partners
- 30,000+ doctors (as of 2025)
- 5,000+ referring doctors across Europe
- Multiple German health insurers
- NHS (United Kingdom)
- Swiss public healthcare system
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Long-Term Cost and Health Impact of a Digital Obesity Intervention in Germany: Economic Modeling Study.JMIR formative research · Aug 24, 2026
Addressing inequalities in access and care in type 1 diabetes - The North-East London Type 1 Diabetes Transformation (NATALIE) project.Primary care diabetes · Jun 1, 2026
Mechanisms of action for digital therapeutics.NPJ digital medicine · Mar 5, 2026
Efficacy of a digital health application for weight management in people with obesity: 6-months results from a randomized controlled trial.International journal of obesity (2005) · Feb 1, 2026
Personalizing a Weight Loss Program Using Cognitive-Behavioral Phenotypes to Improve Engagement and Weight Loss in Adults With Overweight or Obesity: Quasi-Experimental Study.JMIR formative research · Dec 1, 2025
Skin health and biological aging.Nature aging · Jul 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Overall patient satisfaction
Study of 700 NHS patients
NHS patient study
AMODA clinical trial
Dual-action hypertension DiGA
Clinical study showing sustained results
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Oviva
Recent articles published on Oviva's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.